Leadership

CEO

Heeyong Lee

He has been working in the field of sustained release microspheres for more than 20 years since he participated in the development of long acting prostate cancer drug as a post-doctor at the University of Kentucky. Prior to starting G2GBIO, he worked at Peptron. for 15 years as a Head of R&D and Business Development. During that time, he was responsible for developing sustained-release drugs for prostate cancer, acromegaly, and type 2 diabetes and succeeded in commercializing prostate cancer drug through technology transfer and licensing. He also contributed significantly to the Peptron's listing on the KOSDAQ in 2015. He earned his B.S. in Biochemistry at Yonsei University and his M.S. and Ph.D. in life sciences at KAIST.

Senior managing director
Head of R&D

Eunyoung Seol

He has previously been responsible for the development of sustained-release injections at Daewoong Pharmaceuticals, Dong Kuk Pharm, and Peptron. He has a long term expertise throughout the research, clinical, commercialization and spray drying processes and emulsion processes of peptides and small molecules. He graduated from Chungnam National University with a B.S. and a M.S. in Biochemistry.

Senior managing director
Manufacturing Division

Bokman Kim

He served as the director of the Manufacturing Division at Peptron, establishing a sterile microsphere production process using spray drying and overseeing the construction of a clinical factory. Prior to that, he worked for about 16 years at LG Life Sciences, where he directed production of various pharmaceuticals and plant construction. He holds a B.S. in chemical engineering from Chung-Ang University.

Managing director
Business Development

Soojung Lee

She was responsible for licensing and joint development, and IP management at Peptron. Previously, she worked for a consulting firm and managed a drug pricing project through pharmacoeconomic analysis. She received her B.S. in microbiology and M.S. in genetic engineering from Seoul National University.